Berndt Modig Sells 2,291 Shares of Pharvaris (NASDAQ:PHVS) Stock

Posted by Stanley Muller on Jun 19th, 2026

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) CEO Berndt Modig sold 2,291 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $31.07, for a total value of $71,181.37. Following the completion of the sale, the chief executive officer owned 135,209 shares of the company’s stock, valued at $4,200,943.63. The trade was a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Berndt Modig also recently made the following trade(s):

On Monday, May 18th, Berndt Modig sold 2,292 shares of Pharvaris stock. The stock was sold at an average price of $29.22, for a total transaction of $66,972.24.
On Thursday, April 16th, Berndt Modig sold 2,292 shares of Pharvaris stock. The stock was sold at an average price of $28.60, for a total transaction of $65,551.20.
On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The shares were sold at an average price of $27.74, for a total transaction of $647,257.42.

Pharvaris Stock Performance

PHVS stock opened at $32.80 on Friday. Pharvaris N.V. has a 52 week low of $16.72 and a 52 week high of $34.41. The firm’s fifty day moving average is $29.91 and its 200 day moving average is $27.71. The firm has a market cap of $2.15 billion, a P/E ratio of -10.31 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. As a group, analysts forecast that Pharvaris N.V. will post -3.22 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PHVS. GF Fund Management CO. LTD. purchased a new stake in Pharvaris in the 4th quarter worth approximately $35,000. JPMorgan Chase & Co. increased its stake in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Pharvaris during the third quarter valued at approximately $75,000. Barclays PLC bought a new position in shares of Pharvaris during the fourth quarter valued at approximately $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Pharvaris during the fourth quarter valued at approximately $86,000.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on PHVS shares. Royal Bank Of Canada lowered their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Wolfe Research began coverage on Pharvaris in a research report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price objective for the company. Citizens Jmp dropped their price objective on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Finally, UBS Group set a $74.00 target price on shares of Pharvaris in a research note on Wednesday, May 13th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $49.18.

Read Our Latest Analysis on PHVS

About Pharvaris

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.